IL-15 promotes inflammatory T h 17 cells in the intestine

This is the authors' abstract. We don't add key points for this paper.

Ulcerative Colitis (UC) is a chronic gastrointestinal condition with high morbidity. While modern medical therapies have revolutionized the care of UC, 10-25% of patients fail medications and still progress to surgery. Thus, developing new treatments is a core problem in UC. T-cells, especially T h 17 cells, are strongly linked with UC and are major targets of medications in UC. Tissue-resident memory T-cells (T RM ) are a distinct class of T-cells that are highly enriched in the intestine, closely aligned with the microbiota, and are implicated in the pathogenesis of UC. Unlike circulating T-cells, T RM are difficult to target because they do not recirculate. Thus, we focused on cytokines like IL-15 which act as a tissue danger signal and regulate T-cells in situ . We found that the IL15 axis is upregulated in UC and predicts treatment response. IL-15 was redundant for T h 17 differentiation but could activate terminally differentiated T h 17 cells to promote intestinal inflammation. Finally, in CD4 + T RM from patients with UC, IL-15 upregulated RORC , the master transcription factor for T h 17 cells, via a Janus Kinase (JAK)1 pathway. Thus, IL-15 promotes terminally differentiated inflammatory T h 17 cells in the intestine raising the possibility that IL-15 may be a target for UC treatments.